Product Liability

DePuy Hip Implant Settlement Details Emerge

As being reported by numerous news agencies, Johnson & Johnson has agreed to settle thousands of pending lawsuits against its subsidiary DePuy Othopaedics arising from its ASR hip implant. Attorneys for the Plaintiffs and Defendants announced the DePuy hip implant settlement agreement during a settlement conference on November 19, 2013 before the Honorable David S. Katz, judge for the  United States District Court, Northern District of Ohio, Western Division.

Following the settlement conference, details of the ...

continue reading...

Settlement reached in DePuy Hip Implant Lawsuits

The New York Times reports that a tentative deal has been reached to settle thousands of DePuy hip implant lawsuits. The lawsuits were filed against Johnson & Johnson subsidiary DePuy Orthopaedics, alleging premature failure of DePuy’s ASR metal-on-metal hip implants. The settlement, which still requires court approval, could reach up to $4 billion dollars.

Approximately 12,000 hip implant lawsuits have been filed against DePuy Orthopaedics. DePuy recalled the implants in mid-2010.

According to the New York Times, the ...

continue reading...

Johnson & Johnson Guilty Plea Helps Risperdal Lawsuits

After a ten-year long criminal investigation, Johnson & Johnson has entered a guilty plea and will pay $2.2 billion in damages. The U.S. Department of Justice charged the company with promoting the drugs Risperdal and Invega for off-label uses (uses that were not approved by the FDA). These drugs were approved solely for the treatment of schizophrenia, but Johnson & Johnson was promoting them for non-schizophrenic patients—including children, ...

continue reading...

Meningitis pharmacy was violating law

According to a USA Today story about an ongoing fungal meningitis outbreak, the specialty pharmacy responsible has been flagrantly violating both sanitation standards and the terms of the federal laws permitting it to operate.

But the story characterizes the problem not simply as the practices of a single irresponsible business, but a systemic failing that’s permitted “compounding pharmacies” to operate on a large scale under relatively lax regulatory standards.

And patients ...

continue reading...

New blood pressure treatment being tested

ABC 30 out of Fresno, Calif., reports on a clinical trial for a new blood pressure treatment called Renal Denervation.

The proposed treatment would target overactive renal nerves, which can cause blood pressure to skyrocket. Renal nerves transmit information from the kidneys to the brain. In Renal Denervation, doctors insert a needle into an artery in the groin near the kidneys and burn the nerves.

The ABC 30 story quotes a ...

continue reading...

Drug manufacturers agree to review of diabetes drugs

Global drug manufacturers have agreed to cooperate with an independent review of diabetes drugs classified as “incretin mimetics,” which include Byetta and Januvia, in light of a growing body of research suggesting that the drugs may be linked to pancreatic cancer and a potentially deadly inflammation of the pancreas called pancreatitis.

The American Diabetes Association has called for such a review.

A Reuters report on the issue quotes the ADA’s chief scientific ...

continue reading...
Page 5 of 132 «...34567...»